Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
NYU Langone Transplant Institute, NYU Langone Health, New York, NY, USA.
Nat Rev Microbiol. 2023 Apr;21(4):222-235. doi: 10.1038/s41579-022-00821-x. Epub 2022 Nov 16.
New methods and technologies within the field of lung biology are beginning to shed new light into the microbial world of the respiratory tract. Long considered to be a sterile environment, it is now clear that the human lungs are frequently exposed to live microbes and their by-products. The nature of the lung microbiome is quite distinct from other microbial communities inhabiting our bodies such as those in the gut. Notably, the microbiome of the lung exhibits a low biomass and is dominated by dynamic fluxes of microbial immigration and clearance, resulting in a bacterial burden and microbiome composition that is fluid in nature rather than fixed. As our understanding of the microbial ecology of the lung improves, it is becoming increasingly apparent that certain disease states can disrupt the microbial-host interface and ultimately affect disease pathogenesis. In this Review, we provide an overview of lower airway microbial dynamics in health and disease and discuss future work that is required to uncover novel therapeutic targets to improve lung health.
肺部生物学领域的新方法和新技术开始为呼吸道的微生物世界带来新的启示。长期以来,人们一直认为呼吸道是一个无菌的环境,但现在很明显,人类的肺部经常会接触到活的微生物及其产物。肺部微生物组的性质与我们体内其他微生物群落(如肠道中的微生物群落)有很大的不同。值得注意的是,肺部微生物组的生物量较低,其主要特征是微生物的移入和清除的动态通量,导致细菌负担和微生物组组成本质上是流动的,而不是固定的。随着我们对肺部微生物生态的理解的提高,越来越明显的是,某些疾病状态会破坏微生物-宿主界面,并最终影响疾病的发病机制。在这篇综述中,我们概述了健康和疾病状态下下呼吸道微生物的动态变化,并讨论了为了发现改善肺部健康的新的治疗靶点所需的未来工作。